Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Midatech Pharma
Abingdon, Oxfordshire, UK
- Ownership
- Private
- Development stage
- Other
01
Overview
Midatech Pharma has completed Phase I for MidaCore (30% response rate in solid tumors), Phase II for MTX110 (brain tumors) and MTD201 (oncology), with preclinical programs ongoing; anticipates Phase II for Q-Sphera by Q2 2024.[1]
- Therapeutic areas
- OncologyEndocrinologyNeurologyRare Diseases
- Modalities
- NanoparticlePeptides
- Industry
- Biotech
02
Partnerships
University of OxfordMonoSol Rx (MidaSol Therapeutics LP)Immunotope Inc. (Syntara LLC)University of CaliforniaMajor US pharmaceutical company
Beyond the preview
Go deeper on Midatech Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Midatech Pharma.